<!DOCTYPE html>
<html lang="en"><head>
<script src="Acute_pancreatitis_files/libs/clipboard/clipboard.min.js"></script>
<script src="Acute_pancreatitis_files/libs/quarto-html/tabby.min.js"></script>
<script src="Acute_pancreatitis_files/libs/quarto-html/popper.min.js"></script>
<script src="Acute_pancreatitis_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="Acute_pancreatitis_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="Acute_pancreatitis_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="Acute_pancreatitis_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="Acute_pancreatitis_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.5.56">

  <meta name="author" content="Gustavo Santos Paiva Laender Moura">
  <meta name="dcterms.date" content="2025-05-28">
  <title>ESPEN practical guideline on clinical nutrition in ACUTE pancreatitis</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="Acute_pancreatitis_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="Acute_pancreatitis_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="Acute_pancreatitis_files/libs/revealjs/dist/theme/quarto.css">
  <link href="Acute_pancreatitis_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="Acute_pancreatitis_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="Acute_pancreatitis_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="Acute_pancreatitis_files/libs/revealjs/plugin/reveal-chalkboard/font-awesome/css/all.css" rel="stylesheet">
  <link href="Acute_pancreatitis_files/libs/revealjs/plugin/reveal-chalkboard/style.css" rel="stylesheet">
  <link href="Acute_pancreatitis_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    padding-bottom: 0.5rem;
    margin-bottom: 0;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" data-background-image="../logo.png" data-background-position="top right" data-background-size="120px" class="quarto-title-block center">
  <h1 class="title">ESPEN practical guideline on clinical nutrition in ACUTE pancreatitis</h1>
  <p class="subtitle"><a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594">Arvanitakis. M, et al.&nbsp;Clinical Nutrition, February 2024</a></p>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Gustavo Santos Paiva Laender Moura 
</div>
        <p class="quarto-title-affiliation">
            Ribeirão Preto Medical School, University of São Paulo
          </p>
    </div>
</div>

  <p class="date">2025-05-28</p>
</section>
<section>
<section id="introduction" class="title-slide slide level2 center">
<h2>1. Introduction</h2>

</section>
<section id="acute-pancreatitis-ap" class="slide level3">
<h3>Acute pancreatitis (AP)</h3>
<ul>
<li><strong>Prevalence:</strong> Most common acute GI disease requiring hospitalization.</li>
<li><strong>Prognosis:</strong> Favorable in ~80% of cases.</li>
<li><strong>Severe Form:</strong> Acute Necrotizing Pancreatitis (<strong>ANP</strong>) affects ~20%, with:
<ul>
<li>38% early organ failure</li>
<li>38% requiring intervention</li>
<li>15% mortality rate</li>
</ul></li>
<li><strong>Metabolic Impact:</strong> High catabolism—nutritional support is crucial.</li>
<li><strong>Nutritional Strategy:</strong>
<ul>
<li><strong>Enteral Nutrition (EN)</strong> proven superior to Parenteral Nutrition (PN).</li>
<li>Paradigm shift in ANP management over the past decade.</li>
</ul></li>
<li><strong>Current Research Gaps:</strong>
<ul>
<li>Optimal <strong>timing</strong>, <strong>route</strong>, and <strong>type</strong> of EN.</li>
<li>Role of <strong>oral refeeding</strong> still under investigation.</li>
</ul></li>
</ul>
</section></section>
<section id="methodology-overview" class="title-slide slide level2 center">
<h2>2. Methodology Overview</h2>
<ul>
<li><strong>Content:</strong>
<ul>
<li>42 recommendations (19 for acute and 23 for chronic pancreatitis)</li>
<li>6 statements</li>
</ul></li>
<li><strong>Development Process:</strong>
<ul>
<li>Systematic literature search (Dec 1, 2018) based on 31 PICO questions.</li>
<li>Evidence graded using <strong>SIGN system</strong>.</li>
<li>Recommendations classified into four grades: <strong>A, B, 0, GPP</strong>.</li>
</ul></li>
<li><strong>Consensus:</strong>
<ul>
<li>Achieved through a multistage process with % agreement recorded.</li>
</ul></li>
</ul>
</section>

<section>
<section id="acute-pancreatitis" class="title-slide slide level2 center">
<h2>3. Acute pancreatitis</h2>

</section>
<section id="recomendation-1-nutritional-risk" class="slide level3">
<h3>Recomendation 1: Nutritional risk</h3>
<p><strong>All patients with acute pancreatitis (AP)</strong> should be considered at <strong>moderate to high nutritional risk</strong> due to the disease’s <strong>catabolic nature</strong> and its impact on outcomes.</p>
<p><em>(S1, strong consensus, 97 %)</em></p>
<ul>
<li><strong>Mild to Moderate AP:</strong>
<ul>
<li>Most patients recover fully within a week.</li>
<li><strong>Oral feeding</strong> is usually feasible within a few days.</li>
</ul></li>
<li><strong>Severe AP:</strong>
<ul>
<li>Up to <strong>60% develop gut-barrier dysfunction</strong>, increasing risk of:
<ul>
<li><strong>Bacterial translocation</strong></li>
<li><strong>Infected necrosis</strong></li>
</ul></li>
<li>Severe catabolism places these patients at <strong>high nutritional risk</strong>.</li>
</ul></li>
<li><strong>Other At-Risk Groups:</strong>
<ul>
<li><strong>Malnourished patients</strong>, even with mild AP, due to pre-existing deficits.</li>
<li><strong>Patients with high alcohol consumption</strong>, often chronically malnourished.</li>
</ul></li>
</ul>
</section>
<section id="fig.-1-nutritional-management-of-acute-pancreatitis" class="slide level3">
<h3>Fig. 1 Nutritional management of acute pancreatitis</h3>

<img data-src="img/gr1_lrg.png" class="r-stretch"><div class="smaller">
<p>Fig. 1. Nutritional <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/management-of-acute-pancreatitis">management of acute pancreatitis</a>. AP, acute pancreatitis.</p>
</div>
</section></section>
<section>
<section id="mild-to-moderate-disease" class="title-slide slide level2 center">
<h2>3.1. Mild to moderate disease</h2>

</section>
<section id="recomendation-2-nutritional-screening" class="slide level3 scrollable">
<h3>Recomendation 2: Nutritional Screening</h3>
<ol type="1">
<li><p>Use validated tools like <strong>NRS-2002</strong> to screen <strong>all patients with predicted mild to moderate AP</strong> for nutritional risk.</p></li>
<li><p>Patients with <strong>predicted severe AP</strong> are <strong>automatically considered at nutritional risk</strong>—no additional screening needed.</p></li>
</ol>
<p><em>(R1, grade B, strong consensus, 100 %)</em></p>
<ul>
<li><strong>Screening Tools:</strong>
<ul>
<li><a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib12">NRS 2002</a> helps identify patients at nutritional risk.</li>
<li>Validated in hospitalized and critically ill patients [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib13">13</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib14">14</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib15">15</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib16">16</a>].</li>
<li><strong>Not specifically validated for AP patients</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib17">17</a>].</li>
</ul></li>
<li><strong>BMI Considerations:</strong>
<ul>
<li><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/body-mass-index">Body mass index (BMI)</a> is useful for risk assessment:
<ul>
<li><strong>Low BMI:</strong> Indicates pre-existing malnutrition.</li>
<li><strong>Obesity:</strong> Increases risk for <strong>severe AP</strong>, acting as a <strong>disease severity-related nutritional risk</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib18">18</a>].</li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="questão-1" class="slide level3 scrollable">
<h3>Questão 1</h3>
<p>Um médico residente está avaliando um paciente com pancreatite aguda (PA) na enfermaria. Com base nas evidências atuais sobre a fisiopatologia e manejo nutricional da PA, quais das alternativas abaixo são verdadeiras? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li><p>Todo paciente com PA deve ser considerado em risco nutricional moderado a alto, mesmo que apresente boa ingestão oral na admissão.</p></li>
<li><p>A nutrição parenteral deve ser iniciada precocemente em todos os casos de pancreatite necrosante devido à disfunção de barreira intestinal.</p></li>
<li><p>Pacientes com PA leve a moderada não requerem triagem nutricional formal, pois o risco nutricional é considerado baixo.</p></li>
<li><p>O catabolismo exacerbado na PA grave justifica a introdução precoce da nutrição enteral, preferencialmente por sonda jejunal.</p></li>
<li><p>O índice de massa corporal (IMC) pode ser útil na estratificação do risco nutricional, já que tanto a desnutrição quanto a obesidade influenciam negativamente o prognóstico.</p></li>
<li><p>Ferramentas como o NRS-2002 são úteis para triagem nutricional em PA, mas não foram validadas especificamente para essa condição.</p></li>
</ol>
</section>
<section id="questão-1-1" class="slide level3 scrollable">
<h3>Questão 1</h3>
<p>Um médico residente está avaliando um paciente com pancreatite aguda (PA) na enfermaria. Com base nas evidências atuais sobre a fisiopatologia e manejo nutricional da PA, quais das alternativas abaixo são verdadeiras? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li><p><strong>Todo paciente com PA deve ser considerado em risco nutricional moderado a alto, mesmo que apresente boa ingestão oral na admissão. (Correta)</strong></p></li>
<li><p>A nutrição parenteral deve ser iniciada precocemente em todos os casos de pancreatite necrosante devido à disfunção de barreira intestinal. (Incorreta)</p></li>
<li><p>Pacientes com PA leve a moderada não requerem triagem nutricional formal, pois o risco nutricional é considerado baixo. (Incorreta)</p></li>
<li><p><strong>O catabolismo exacerbado na PA grave justifica a introdução precoce da nutrição enteral, preferencialmente por sonda jejunal. (Correta)</strong></p></li>
<li><p><strong>O índice de massa corporal (IMC) pode ser útil na estratificação do risco nutricional, já que tanto a desnutrição quanto a obesidade influenciam negativamente o prognóstico. (Correta)</strong></p></li>
<li><p><strong>Ferramentas como o NRS-2002 são úteis para triagem nutricional em PA, mas não foram validadas especificamente para essa condição. (Correta)</strong></p></li>
</ol>
</section>
<section id="recomendation-3-early-oral-feeding-in-mild-to-moderate-ap" class="slide level3">
<h3>Recomendation 3: Early Oral Feeding in Mild to Moderate AP</h3>
<p>Begin <strong>oral feeding</strong> as soon as <strong>clinically tolerated</strong>, regardless of <strong>serum <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/triacylglycerol-lipase">lipase</a> levels</strong> in patients with predicted mild/moderate AP.</p>
<p><em>(R2, grade A, strong consensus, 100 %)</em></p>
<ul>
<li><strong>Evidence from 4 <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/randomized-controlled-trial">RCTs</a>:</strong>
<ul>
<li><strong>Early oral feeding</strong> is safe and well-tolerated.</li>
<li>Leads to <strong>shorter hospital stay</strong> compared to conventional strategies.</li>
<li><em>Conventional feeding</em> strategy is NOT recommended. It waits for:
<ul>
<li>Enzyme reduction</li>
<li>Pain resolution</li>
<li>Return of bowel function</li>
</ul></li>
</ul></li>
<li><strong>Key Finding:</strong>
<ul>
<li>One RCT showed that feeding is safe <strong>regardless of serum lipase levels</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib8">8</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib19">19</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib20">20</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib21">21</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib22">22</a>].</li>
</ul></li>
</ul>
</section>
<section id="recomendation-4-low-fat-soft-oral-diet" class="slide level3">
<h3>Recomendation 4: Low-fat, soft oral diet</h3>
<p>Use a <strong>low-fat, soft oral diet</strong> when restarting feeding in patients with <strong>mild/moderate AP</strong>.</p>
<p><em>(R3, grade A, strong consensus, 100 %)</em></p>
<ul>
<li><strong>Soft diets</strong> improve <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/caloric-intake">caloric intake</a> and are <strong>as well tolerated</strong> as <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/clear-liquid-diet">clear liquid diets</a> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib22">22</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib23">23</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib24">24</a>].</li>
<li>A <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib25">meta-analysis</a> confirmed early oral feeding is feasible and reduces length of stay.</li>
<li><strong>16.3% of patients may experience feeding intolerance</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib26">26</a>].</li>
<li><strong>Special Consideration – <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/hyperlipidemia">Hyperlipidemia</a> Induced AP:</strong>
<ul>
<li>Accounts for <strong>4–10% of AP cases</strong>.</li>
<li>Associated with <strong>worse prognosis</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib27">27</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib28">28</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib29">29</a>].</li>
<li>Management includes:
<ul>
<li><strong>Nil by mouth</strong> for 24–48h initially.</li>
<li><strong>Dietary modifications</strong> and <strong>lipid-lowering medications</strong>.</li>
<li>In-hospital treatment with <strong>insulin</strong>, <strong>heparin</strong>, and possibly <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/plasmapheresis"><strong>plasmapheresis</strong></a>.</li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="recomendation-5-enteral-nutrition-in-case-of-intolerance-to-oral-feeding" class="slide level3">
<h3>Recomendation 5: Enteral nutrition in case of intolerance to oral feeding</h3>
<p>When <strong>oral feeding is not tolerated</strong>, prioritize <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/parenteral-nutrition"><strong>enteral nutrition</strong></a> over parenteral nutrition in <strong>acute pancreatitis (AP)</strong>.</p>
<p><em>(R4, grade A, strong consensus, 97 %)</em></p>
<ul>
<li><strong>Physiological Benefits of EN:</strong>
<ul>
<li>Preserves <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/mucosa">gut mucosa</a> integrity.</li>
<li>Stimulates <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/intestine-motility">intestinal motility</a>.</li>
<li>Prevents <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/bacterial-overgrowth">bacterial overgrowth</a>.</li>
<li>Increases <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/splanchnic-blood-flow">splanchnic blood flow</a> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib9">9</a>].</li>
</ul></li>
<li><strong>Evidence Base:</strong>: <strong>12 RCTs</strong> and <strong>11 systematic reviews/meta-analyses</strong>. <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib34"><strong>Cochrane-standard meta-analysis</strong></a>:
<ul>
<li><strong>Safe and well-tolerated</strong> in severe AP.</li>
<li>Compared to PN, EN reduces:
<ul>
<li><strong>Mortality by 50%</strong> (OR 0.50)</li>
<li><strong>Infection rate</strong> (OR 0.39)</li>
<li><strong>Multi-organ failure</strong> (OR 0.55)</li>
<li><strong>Need for surgery</strong> (OR 0.44)</li>
</ul></li>
<li>In <strong>severe AP only</strong>, mortality reduced by <strong>&gt;80%</strong> (OR 0.18).</li>
</ul></li>
<li><strong>Recent Confirmations:</strong>
<ul>
<li>Latest meta-analyses in critically ill AP patients show EN significantly reduces:
<ul>
<li><strong>Mortality</strong> (RR 0.36)</li>
<li><strong>Multiple organ failure</strong> (RR 0.39) [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib38">38</a>].</li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="questão-2" class="slide level3 scrollable">
<h3>Questão 2</h3>
<p>Você está acompanhando um paciente internado com diagnóstico de pancreatite aguda leve a moderada. Considerando as recomendações nutricionais mais atualizadas e baseadas em evidências para essa condição, quais das afirmações a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A introdução da dieta oral deve aguardar a normalização das enzimas pancreáticas, resolução da dor e recuperação da função intestinal.</li>
<li>A alimentação enteral está indicada apenas em casos de pancreatite aguda grave, sendo contraindicada em casos leves ou moderados.</li>
<li>A dieta oral pode ser iniciada assim que o paciente tolerar clinicamente, independentemente dos níveis séricos de lipase.</li>
<li>Em pacientes com intolerância à dieta oral, a nutrição enteral é preferida à parenteral por seus efeitos benéficos sobre a integridade da mucosa intestinal e menor risco de infecções.</li>
<li>Em casos de pancreatite induzida por hiperlipidemia, a conduta pode incluir jejum por 24 a 48 horas, dieta pobre em gordura e uso de medicamentos redutores de lipídios.</li>
<li>Dietas líquidas claras são mais bem toleradas e preferíveis às dietas pastosas no reinício da alimentação em pacientes com pancreatite aguda leve a moderada.</li>
</ol>
</section>
<section id="questão-2-1" class="slide level3 scrollable">
<h3>Questão 2</h3>
<p>Você está acompanhando um paciente internado com diagnóstico de pancreatite aguda leve a moderada. Considerando as recomendações nutricionais mais atualizadas e baseadas em evidências para essa condição, quais das afirmações a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A introdução da dieta oral deve aguardar a normalização das enzimas pancreáticas, resolução da dor e recuperação da função intestinal. (Incorreta)</li>
<li>A alimentação enteral está indicada apenas em casos de pancreatite aguda grave, sendo contraindicada em casos leves ou moderados. (Incorreta)</li>
<li>A dieta oral pode ser iniciada assim que o paciente tolerar clinicamente, independentemente dos níveis séricos de lipase. (Correta)</li>
<li>Em pacientes com intolerância à dieta oral, a nutrição enteral é preferida à parenteral por seus efeitos benéficos sobre a integridade da mucosa intestinal e menor risco de infecções. (Correta)</li>
<li>Em casos de pancreatite induzida por hiperlipidemia, a conduta pode incluir jejum por 24 a 48 horas, dieta pobre em gordura e uso de hipolipemiantes. (Correta)</li>
<li>Dietas líquidas claras são mais bem toleradas e preferíveis às dietas pastosas no reinício da alimentação em pacientes com pancreatite aguda leve a moderada. (Incorreta)</li>
</ol>
</section>
<section id="recomendation-6-en-timing" class="slide level3">
<h3>Recomendation 6: EN Timing</h3>
<p><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/enteric-feeding"><strong>Enteral nutrition</strong></a> <strong>should be started early, within 24–72 h of admission, in case of intolerance to oral feeding.</strong></p>
<p><em>(R5, grade B, strong consensus, 92 %)</em></p>
<ul>
<li><strong>Meta-Analyses Findings:</strong>. Early EN within <strong>24h</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib41">41</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib42">42</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib43">43</a>] or <strong>48h</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib44">44</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib45">45</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib46">46</a>] is:
<ul>
<li><strong>Safe, well-tolerated, and beneficial.</strong></li>
<li>Reduces <strong>mortality, organ failure, and infections.</strong></li>
<li><strong>Limitation:</strong> Most included studies had PN as the control group, not delayed EN.</li>
</ul></li>
<li><strong>RCTs with Different Findings:</strong>. Two RCTs [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib43">43</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib47">47</a>] showed:
<ul>
<li><strong>No difference</strong> in major infection or mortality between:
<ul>
<li><strong>Early EN (within 24h)</strong> vs.</li>
<li><strong>Oral diet after 72h.</strong></li>
</ul></li>
</ul></li>
<li><strong>Optimal Timing Insight:</strong>. A <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/prospective-cohort-study">prospective cohort study</a> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib48">48</a>] suggests:
<ul>
<li><strong>Day 3 after admission</strong> is the optimal cut-off for EN.</li>
<li>Associated with:
<ul>
<li><strong>Reduced secondary infections.</strong></li>
<li><strong>Better nutritional status.</strong></li>
<li><strong>Improved tolerance.</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="recomendation-7-formula-selection" class="slide level3">
<h3>Recomendation 7: Formula selection</h3>
<p>Use a <strong>standard polymeric formula</strong> for enteral nutrition in <strong>acute pancreatitis</strong> patients.</p>
<p><em>(R6, grade A, strong consensus, 97 %)</em></p>
<ul>
<li><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/malabsorption">Semi-elemental</a> and <strong>polymeric formulas</strong> are <strong>safe, feasible, and well-tolerated</strong> in AP patients.
<ul>
<li>Small RCT (30 patients) found both formulas effective, but <strong>semi-elemental</strong> diets showed:
<ul>
<li><strong>Shorter length of stay</strong> (23 ± 2 vs.&nbsp;27 ± 1 days, p = 0.006).</li>
<li><strong>Better weight maintenance</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib49">49</a>].</li>
</ul></li>
<li>Meta-analysis by <strong>Petrov et al.</strong> (428 patients) showed:
<ul>
<li><strong>No difference</strong> in tolerance, infection, or mortality between formulas [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib50">50</a>].</li>
</ul></li>
<li>Larger meta-analysis (15 trials, 1376 participants) also found:
<ul>
<li><strong>No evidence favoring any specific formula</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib51">51</a>].</li>
</ul></li>
</ul></li>
<li><strong>Clinical Consideration:</strong>
<ul>
<li>In patients with <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/malabsorption"><strong>malabsorption</strong></a> (often in severe AP), <strong>semi-elemental diets may be preferable</strong>.</li>
</ul></li>
</ul>
</section>
<section id="recomendation-8-en-route" class="slide level3 scrollable">
<h3>Recomendation 8: EN Route</h3>
<ol type="1">
<li>If EN is required in patients with AP, use a <strong>nasogastric tube</strong>.</li>
<li>A <strong>nasojejunal tube</strong> is preferred in case of <em>digestive intolerance</em> (e.g., pain, vomiting).</li>
</ol>
<p><em>(R7, grade B, strong consensus, 95 %)</em></p>
<ul>
<li><strong>3 RCTs</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib52">52</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib53">53</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib54">54</a>] found <strong>no differences</strong> between nasogastric and nasojejunal routes in (1) <strong>tolerance</strong>, (2) <strong>complications</strong>, and (3) <strong>mortality</strong>.</li>
<li><strong>4 meta-analyses</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib55">55</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib56">56</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib57">57</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib58">58</a>] confirm:
<ul>
<li><strong>Nasogastric feeding is safe, feasible, and effective</strong>.</li>
<li>No increase in mortality, complications, or hospital stay compared to nasojejunal feeding.</li>
</ul></li>
<li><strong>Practical Considerations:</strong>
<ul>
<li><strong>Nasogastric tubes:</strong> Easier, cheaper, and more convenient.</li>
<li><strong>Digestive intolerance (~15%)</strong> may occur due to:
<ul>
<li><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/stomach-paresis">Delayed gastric emptying</a>.</li>
<li>Gastric outlet obstruction (GOO) syndrome (mechanical or functional blockage at the distal stomach, pylorus, or proximal duodenum).</li>
</ul></li>
<li>In such cases, <strong>nasojejunal feeding</strong> is preferred.</li>
</ul></li>
<li><strong>Limitations:</strong> trials included <strong>small sample sizes</strong> and <strong>varied definitions</strong> of severe AP.</li>
</ul>
</section>
<section id="questão-3" class="slide level3 scrollable">
<h3>Questão 3</h3>
<p>Você está em plantão na UTI e assume o cuidado de um paciente com pancreatite aguda grave que não tolerou alimentação oral nas primeiras 24 horas. Com base nas evidências mais atualizadas sobre nutrição enteral (NE) nesse cenário, quais das alternativas a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A nutrição enteral deve ser iniciada precocemente, preferencialmente entre 24 e 72 horas da admissão, nos pacientes que não toleram via oral.</li>
<li>A via nasojejunal deve ser sempre preferida à via nasogástrica, pois garante maior segurança, tolerância e menor taxa de complicações.</li>
<li>As evidências atuais favorecem o uso de fórmulas semi-elementares em todos os pacientes, por apresentarem melhores desfechos clínicos em estudos randomizados de grande porte.</li>
<li>Embora não haja superioridade geral, pacientes com pancreatite aguda e má absorção podem se beneficiar de dietas semi-elementares.</li>
<li>Meta-análises e estudos clínicos indicam que a NE precoce reduz mortalidade, falência orgânica e infecções, ainda que parte das evidências tenha comparado com nutrição parenteral, e não com NE tardia.</li>
<li>Em caso de intolerância digestiva à NE por sonda nasogástrica (ex.: náuseas, vômitos ou dor), deve-se considerar a troca para sonda nasojejunal.</li>
</ol>
</section>
<section id="questão-3-1" class="slide level3 scrollable">
<h3>Questão 3</h3>
<p>Você está em plantão na UTI e assume o cuidado de um paciente com pancreatite aguda grave que não tolerou alimentação oral nas primeiras 24 horas. Com base nas evidências mais atualizadas sobre nutrição enteral (NE) nesse cenário, quais das alternativas a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A nutrição enteral deve ser iniciada precocemente, preferencialmente entre 24 e 72 horas da admissão, nos pacientes que não toleram via oral. (Correta)</li>
<li>A via nasojejunal deve ser sempre preferida à via nasogástrica, pois garante maior segurança, tolerância e menor taxa de complicações. (Incorreta)</li>
<li>As evidências atuais favorecem o uso de fórmulas semi-elementares em todos os pacientes, por apresentarem melhores desfechos clínicos em estudos randomizados de grande porte. (Incorreta)</li>
<li>Embora não haja superioridade geral, pacientes com pancreatite aguda e má absorção podem se beneficiar de dietas semi-elementares. (Correta)</li>
<li>Meta-análises e estudos clínicos indicam que a NE precoce reduz mortalidade, falência orgânica e infecções, ainda que parte das evidências tenha comparado com nutrição parenteral, e não com NE tardia. (Correta)</li>
<li>Em caso de intolerância digestiva à NE por sonda nasogástrica (ex.: náuseas, vômitos ou dor), deve-se considerar a troca para sonda nasojejunal. (Correta)</li>
</ol>
</section>
<section id="fig.-2.-management-of-mild-to-moderate-acute-pancreatitis." class="slide level3">
<h3>Fig. 2. Management of mild to moderate acute pancreatitis.</h3>

<img data-src="img/gr2_lrg.png" class="r-stretch"><div class="smaller">
<p>Fig. 2. Management of mild to moderate acute pancreatitis. AP, acute pancreatitis; EN, enteral nutrition; NRS-2002, Nutritional Risk Screening – 2002; PN, parenteral nutrition</p>
</div>
</section></section>
<section>
<section id="severe-acute-pancreatitis" class="title-slide slide level2 center">
<h2>3.2. Severe Acute pancreatitis</h2>

</section>
<section id="recomendation-9-pn-in-case-of-intolerance-of-en" class="slide level3">
<h3>Recomendation 9: PN in case of intolerance of EN</h3>
<p><strong>PN should be used</strong> in patients with acute pancreatitis who:</p>
<ul>
<li><strong>Cannot tolerate <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/nutritional-requirement">enteral nutrition (EN)</a></strong>.</li>
<li><strong>Cannot meet nutritional targets via EN.</strong></li>
<li><strong>Have contraindications for EN.</strong></li>
</ul>
<p><em>(R8, grade GPP, strong consensus, 97 %)</em></p>
<ul>
<li><strong>Rationale:</strong>
<ul>
<li><strong>EN is the preferred route</strong> due to superior outcomes.<br>
</li>
<li><strong>PN is reserved for cases of EN failure or contraindications.</strong></li>
</ul></li>
<li><strong>Contraindications for EN include:</strong>
<ul>
<li><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/bowel-obstruction">Bowel obstruction</a>.<br>
</li>
<li><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/abdominal-compartment-syndrome">Abdominal compartment syndrome</a>.<br>
</li>
<li><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/paralytic-ileus">Paralytic ileus</a>.<br>
</li>
<li><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/mesenteric-ischemia">Mesenteric ischemia</a> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib59">59</a>].</li>
</ul></li>
<li><strong>Clinical Insight:</strong>
<ul>
<li>About <strong>20% of severe AP patients</strong> present with complications that are <strong>absolute or relative contraindications for EN</strong>, similar to other critically ill populations [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib16">16</a>].</li>
</ul></li>
</ul>
</section>
<section id="recomendation-10-glutamine-in-pn" class="slide level3 scrollable">
<h3>Recomendation 10: Glutamine in PN</h3>
<ol type="1">
<li>When <strong>EN is not feasible</strong> and <strong>PN is indicated</strong>, parenteral glutamine should be supplemented at <strong>0.20 g/kg/day of L-glutamine</strong>.</li>
<li><strong>No role for other forms of immunonutrition</strong> in severe AP.</li>
</ol>
<p><em>(R16, grade B, strong consensus, 94 %)</em></p>
<ul>
<li><strong>Initial meta-analysis (11 RCTs)</strong>:
<ul>
<li>Mixed results for antioxidants; benefits mainly from <strong>glutamine</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib60">60</a>].</li>
</ul></li>
<li><strong>Cochrane Review:</strong>
<ul>
<li>Very low-quality evidence — <strong>no effect on mortality</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib61">61</a>].</li>
</ul></li>
<li><strong>Glutamine-specific meta-analyses - 4 meta-analyses</strong> consistently showed:
<ul>
<li>Reduced <strong>infection rates</strong> and <strong>mortality</strong>.<br>
</li>
<li>Benefits observed <strong>only with PN</strong>, NOT enteral nutrition [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib62">62</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib63">63</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib64">64</a>].</li>
<li>Improved <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/serum-albumin">serum albumin</a> and reduced C-reactive protein.</li>
</ul></li>
<li><strong>Limitations:</strong>. High <strong>risk of bias</strong> due to:
<ul>
<li><strong>Small sample sizes</strong>.<br>
</li>
<li><strong>Study heterogeneity</strong>.<br>
</li>
<li><strong>Confounding factors</strong>.</li>
</ul></li>
</ul>
</section>
<section id="recomendation-11-probiotics-not-recommended" class="slide level3">
<h3>Recomendation 11: Probiotics NOT recommended</h3>
<p><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/probiotic-agent"><strong>Probiotics</strong></a> <strong>are contraindicated in patients with severe acute pancreatitis</strong> due to lack of benefit and potential harm.</p>
<p><em>(R17, grade 0, consensus, 89 %)</em></p>
<ul>
<li>Meta-analysis of <strong>6 RCTs (536 patients)</strong> showed <strong>no benefit of probiotics</strong> on:
<ul>
<li>Pancreatic infection rates<br>
</li>
<li>Overall infections<br>
</li>
<li>Operation rates<br>
</li>
<li>Hospital stay<br>
</li>
<li>Mortality [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib65">65</a>].</li>
</ul></li>
<li><strong>Significant heterogeneity</strong> in:
<ul>
<li>Strain types<br>
</li>
<li>Dosages<br>
</li>
<li>Treatment durations</li>
</ul></li>
<li>One RCT reported <strong>increased mortality</strong> in the probiotic group despite similar infection rates [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib66">66</a>].</li>
</ul>
</section>
<section id="recomendation-12-pancreatic-enzymes-not-recommended" class="slide level3">
<h3>Recomendation 12: Pancreatic enzymes NOT recommended</h3>
<p><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/pancreas-enzyme"><strong>Pancreatic enzymes</strong></a> <strong>should not be supplemented generally</strong> except in patients with obvious <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/exocrine-pancreatic-insufficiency"><strong>pancreatic exocrine insufficiency (PEI)</strong></a>.</p>
<p><em>(R18, grade B, strong consensus, 97 %)</em></p>
<ul>
<li>Only <strong>2 small RCTs (78 patients total)</strong>:
<ul>
<li><strong>Kahl et al.</strong>:
<ul>
<li>20/56 had low fecal <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/elastase">elastase</a> indicating PEI.</li>
<li>Slight improvement with enzymes, <strong>not statistically significant</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib67">67</a>].<br>
</li>
</ul></li>
<li><strong>Patankar et al.</strong>:
<ul>
<li><strong>No significant difference</strong> in lab or clinical outcomes [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib68">68</a>].</li>
</ul></li>
</ul></li>
<li><strong>Clinical Guidance:</strong>
<ul>
<li><strong>Do not prescribe enzymes routinely.</strong><br>
</li>
<li>Indicated only if:
<ul>
<li><strong>Documented PEI.</strong><br>
</li>
<li><strong>Malabsorption with <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/steatorrhea">steatorrhea</a>.</strong></li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="questão-4" class="slide level3 scrollable">
<h3>Questão 4</h3>
<p>Durante a discussão de um caso de pancreatite aguda grave na UTI, um colega sugere intervenções nutricionais e terapêuticas diversas. Com base nas diretrizes e nas evidências científicas disponíveis, quais das alternativas a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A nutrição parenteral deve ser iniciada em todos os pacientes com pancreatite aguda grave, independentemente da tolerância à via enteral.</li>
<li>A suplementação de glutamina na nutrição parenteral pode ser benéfica, reduzindo infecções e mortalidade, mas não há benefícios da sua suplementação se o paciente estiver recebendo nutrição enteral exclusiva.</li>
<li>Probióticos são indicados para pacientes com pancreatite aguda grave, pois reduzem infecções e tempo de internação.</li>
<li>A suplementação de enzimas pancreáticas é considerada suporte nutricional padrão em pacientes com pancreatite aguda grave.</li>
<li>A nutrição parenteral está indicada quando não é possível atingir as metas nutricionais por via enteral, ou quando há contraindicações do uso da via enteral, como obstrução intestinal ou isquemia mesentérica.</li>
</ol>
</section>
<section id="questão-4-1" class="slide level3 scrollable">
<h3>Questão 4</h3>
<p>Durante a discussão de um caso de pancreatite aguda grave na UTI, um colega sugere intervenções nutricionais e terapêuticas diversas. Com base nas diretrizes e nas evidências científicas disponíveis, quais das alternativas a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A nutrição parenteral deve ser iniciada em todos os pacientes com pancreatite aguda grave, independentemente da tolerância à via enteral. (Incorreta)</li>
<li>A suplementação de glutamina na nutrição parenteral pode ser benéfica, reduzindo infecções e mortalidade, mas não há benefícios da sua suplementação se o paciente estiver recebendo nutrição enteral exclusiva. (Correta)</li>
<li>Probióticos são indicados para pacientes com pancreatite aguda grave, pois reduzem infecções e tempo de internação. (Incorreta)</li>
<li>A suplementação de enzimas pancreáticas é considerada suporte nutricional padrão em pacientes com pancreatite aguda grave. (Incorreta)</li>
<li>A nutrição parenteral está indicada quando não é possível atingir as metas nutricionais por via enteral, ou quando há contraindicações do uso da via enteral, como obstrução intestinal ou isquemia mesentérica. (Correta)</li>
</ol>
</section>
<section id="fig.-3.-management-of-severe-pancreatitis" class="slide level3">
<h3>Fig. 3. Management of severe pancreatitis</h3>

<img data-src="img/gr3_lrg.png" class="r-stretch"><div class="smaller">
<p>Fig. 3. Management of severe <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/pancreatitis">pancreatitis</a>. AP, acute pancreatitis; EN, enteral nutrition; PEI, pancreatic exocrine insufficiency; PN, parenteral nutrition.</p>
</div>
</section></section>
<section>
<section id="severe-acute-pancreatitis-with-necrosectomy" class="title-slide slide level2 center">
<h2>3.3. Severe Acute pancreatitis with Necrosectomy</h2>

</section>
<section id="recomendation-13-early-oral-feeding-after-minimally-invasive-necrosectomy" class="slide level3">
<h3>Recomendation 13: Early Oral Feeding After Minimally Invasive Necrosectomy</h3>
<p><strong>Oral food intake is safe and feasible</strong> post-procedure and should be started within 24 hours if: - Hemodynamic stability is maintained - No signs of sepsis or gastric emptying issues are present</p>
<p><strong>(R9, grade GPP, strong consensus, 95 %)</strong></p>
<ul>
<li>Patients with <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/acute-hemorrhagic-pancreatitis"><strong>acute necrotizing pancreatitis (ANP)</strong></a> have higher risks of:
<ul>
<li><strong>Multiple organ failure</strong></li>
<li><strong>Infected necrosis</strong></li>
<li><strong>Mortality</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib69">69</a>].</li>
</ul></li>
<li><strong>Surgical Advances:</strong> <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/minimally-invasive-procedure"><strong>Minimally invasive techniques</strong></a> (step-up approach) are now standard, replacing open surgery due to better outcomes [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib70">70</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib71">71</a>].</li>
<li><strong>Nutritional Approach</strong> - In a comparative trial: [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib72">72</a>]:
<ul>
<li><strong>Oral nutrition</strong> was attempted first.</li>
<li>If not tolerated → <strong>nasojejunal EN</strong>.</li>
<li>If EN contraindicated → <strong>parenteral nutrition (PN)</strong>.</li>
<li><strong>Conclusion:</strong> Early oral feeding is <strong>safe and feasible</strong> following minimally invasive necrosectomy, when clinically appropriate.</li>
</ul></li>
</ul>
</section>
<section id="recomendation-14-en-after-necrosectomy-in-oral-feeding-intoleranceinsufficiency" class="slide level3">
<h3>Recomendation 14: EN After Necrosectomy in oral feeding intolerance/insufficiency</h3>
<p>In patients <strong>unable to tolerate oral feeding</strong> after minimally invasive necrosectomy, use <strong>enteral nutrition (EN) via nasojejunal tube</strong> as the <strong>preferred route</strong>.</p>
<p><em>(R10, grade B, strong consensus, 91 %)</em></p>
<ul>
<li>Supported by small series and trials showing that <strong>nasojejunal feeding is safe and feasible</strong>.
<ul>
<li><strong>RCT by Bakker et al.</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib43">43</a>]:
<ul>
<li>No difference in outcomes between <strong>early EN (nasojejunal within 24h)</strong> and <strong>oral feeding after 72h</strong>.</li>
<li>Included various procedures: percutaneous drainage, endoscopic/surgical necrosectomy.</li>
</ul></li>
<li><strong>Retrospective study (37 patients):</strong>
<ul>
<li><strong>Oral feeding within 24–48h</strong> after laparoscopic transgastric necrosectomy was <strong>safe and feasible</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib64">64</a>].</li>
</ul></li>
<li><strong>Prospective study (40 patients):</strong>
<ul>
<li><strong>Nasojejunal EN preferred</strong> after video-assisted retroperitoneal <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/debridement">debridement</a>.</li>
<li>PN used only if EN was not tolerated [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib65">65</a>].</li>
</ul></li>
</ul></li>
<li><strong>Conclusion:</strong>
<ul>
<li><strong>Nasojejunal feeding is the preferred option</strong> when oral intake is not possible following minimally invasive necrosectomy.</li>
</ul></li>
</ul>
</section>
<section id="recomendation-15-complementary-or-exclusive-pn-in-case-of-intolerance-to-en" class="slide level3">
<h3>Recomendation 15: Complementary or exclusive PN in case of intolerance to EN</h3>
<p><strong>Parenteral nutrition (PN)</strong> is indicated for patients after <strong>minimally invasive necrosectomy</strong> when: - <strong>Enteral nutrition (EN) is not tolerated.</strong> - EN does not meet <strong>nutritional targets.</strong> - <strong>Contraindications to EN</strong> are present.</p>
<p><em>(R11, grade GPP, strong consensus, 94 %)</em></p>
<ul>
<li><strong>Clinical Insight:</strong>
<ul>
<li>Consistent with previous recommendations (<strong>10 and 11</strong>).</li>
<li>PN is a <strong>backup strategy</strong>, not the first choice.</li>
<li>Use PN to ensure <strong>adequate nutritional support</strong> when EN is not feasible or fails.</li>
</ul></li>
<li><strong>Conclusion:</strong>
<ul>
<li>In post-necrosectomy patients, <strong>PN is indicated if EN is not possible</strong> to meet the patient’s metabolic and recovery needs.</li>
</ul></li>
</ul>
</section>
<section id="questão-5" class="slide level3 scrollable">
<h3>Questão 5</h3>
<p>Durante a evolução de um paciente com pancreatite aguda necrosante submetido a necrosectomia minimamente invasiva, você deve planejar sua estratégia de suporte nutricional. Com base nas recomendações mais recentes, quais das alternativas abaixo estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A introdução da alimentação oral pode ser considerada dentro de 24 horas após a necrosectomia, desde que o paciente esteja hemodinamicamente estável e sem sinais de sepse ou distúrbios do esvaziamento gástrico. (Correta)</li>
<li>A nutrição parenteral é preferida à enteral nos primeiros dias após necrosectomia devido à alta frequência de intolerância e risco infeccioso. (Incorreta)</li>
<li>Em caso de intolerância à via oral após a necrosectomia, a nutrição enteral deve ser iniciada precodemente por via nasogástrica, e a via nasojejunal é indicada em caso de falha na via nasogástrica. (Incorreta)</li>
<li>A nutrição parenteral pode ser utilizada como complemento ou substituto caso a nutrição enteral não seja tolerada, não atinja as metas calóricas ou esteja contraindicada. (Correta)</li>
<li>A escolha da via nutricional após necrosectomia deve seguir uma abordagem escalonada: oral → enteral (nasojejunal) → parenteral, conforme tolerância e condição clínica. (Correta)</li>
</ol>
</section>
<section id="questão-5-1" class="slide level3 scrollable">
<h3>Questão 5</h3>
<p>Durante a evolução de um paciente com pancreatite aguda necrosante submetido a necrosectomia minimamente invasiva, você deve planejar sua estratégia de suporte nutricional. Com base nas recomendações mais recentes, quais das alternativas abaixo estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>A introdução da alimentação oral pode ser considerada dentro de 24 horas após a necrosectomia, desde que o paciente esteja hemodinamicamente estável e sem sinais de sepse ou distúrbios do esvaziamento gástrico. (Correta)</li>
<li>A nutrição parenteral é preferida à enteral nos primeiros dias após necrosectomia devido à alta frequência de intolerância e risco infeccioso. (Incorreta)</li>
<li>Em caso de intolerância à via oral após a necrosectomia, a nutrição enteral deve ser iniciada precodemente por via nasogástrica, e a via nasojejunal é indicada em caso de falha na via nasogástrica. (Incorreta)</li>
<li>A nutrição parenteral pode ser utilizada como complemento ou substituto caso a nutrição enteral não seja tolerada, não atinja as metas calóricas ou esteja contraindicada. (Correta)</li>
<li>A escolha da via nutricional após necrosectomia deve seguir uma abordagem escalonada: oral → enteral (nasojejunal) → parenteral, conforme tolerância e condição clínica. (Correta)</li>
</ol>
</section></section>
<section>
<section id="intra-abdominal-hypertension" class="title-slide slide level2 center">
<h2>Intra-abdominal hypertension</h2>

</section>
<section id="intra-abdominal-hypertension-iah" class="slide level3 scrollable">
<h3>Intra-abdominal Hypertension (IAH)</h3>
<ul>
<li><p><strong>Normal IAP</strong> in critically ill patients is typically ~5–7 mmHg.</p></li>
<li><p><strong>IAH</strong> is defined as a <strong>sustained IAP ≥12 mmHg</strong>.</p></li>
<li><p><strong>Abdominal Compartment Syndrome (ACS)</strong> is defined as:</p>
<ol type="1">
<li><strong>sustained IAP &gt;20 mmHg</strong> and</li>
<li><strong>new organ dysfunction/failure</strong>.</li>
</ol></li>
</ul>
<table class="caption-top">
<thead>
<tr class="header">
<th><strong>Grade</strong></th>
<th><strong>Intra-abdominal Pressure (IAP)</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Grade I</td>
<td>12–15 mmHg</td>
</tr>
<tr class="even">
<td>Grade II</td>
<td>16–20 mmHg</td>
</tr>
<tr class="odd">
<td>Grade III</td>
<td>21–25 mmHg</td>
</tr>
<tr class="even">
<td>Grade IV</td>
<td>&gt;25 mmHg</td>
</tr>
</tbody>
</table>
<div class="smaller">
<p>Source: World Society of the Abdominal Compartment Syndrome (WSACS)</p>
</div>
</section>
<section id="recomendation-16-intra-abdominal-pressure-15-mmhg" class="slide level3">
<h3>Recomendation 16: Intra-abdominal pressure &lt; 15 mmHg</h3>
<p>For patients with <strong>severe acute pancreatitis (AP)</strong> and <strong>intra-abdominal pressure (IAP) &lt;15 mmHg</strong>:</p>
<ul>
<li><strong>Early enteral nutrition (EN)</strong> should be initiated.</li>
<li><strong>Nasojejunal tube</strong> is preferred, but <strong>nasogastric</strong> is acceptable.</li>
<li><strong>Monitor IAP and clinical status continuously</strong> during EN.</li>
</ul>
<p><strong>(R12, grade A, strong consensus, 91 %)</strong></p>
<ul>
<li><strong>Rationale and Evidence:</strong>
<ul>
<li>While EN reduces mortality and infections, it may elevate <strong>IAP</strong>, risking <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/compartment-syndrome"><strong>abdominal compartment syndrome (ACS)</strong></a> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib73">73</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib74">74</a>].</li>
<li>Observational study (274 patients):
<ul>
<li><strong>103 developed ACS</strong>.</li>
<li>EN intolerance was higher in patients with <strong>grade III–IV intra-abdominal hypertension (IAH)</strong>; <strong>59% required PN</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib75">75</a>].</li>
</ul></li>
<li>RCT (60 patients) found:
<ul>
<li><strong>Early EN when IAP &lt;15 mmHg</strong> prevents progression to IAH [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib76">76</a>].</li>
</ul></li>
</ul></li>
<li><strong>Conclusion:</strong>
<ul>
<li><strong>Start EN early if IAP &lt;15 mmHg.</strong></li>
<li><strong>Monitor IAP closely</strong> to avoid complications related to rising intra-abdominal pressure.</li>
</ul></li>
</ul>
</section>
<section id="recomendation-17-en-in-severe-ap-with-iap-15-mmhg" class="slide level3">
<h3>Recomendation 17: EN in Severe AP with IAP &gt;15 mmHg</h3>
<p>In patients with <strong>severe acute pancreatitis (AP)</strong> and <strong>intra-abdominal pressure (IAP) &gt;15 mmHg</strong>:</p>
<ul>
<li>Start <strong>enteral nutrition (EN) via nasojejunal tube</strong> at <strong>20 mL/h</strong>.</li>
<li>Gradually <strong>increase the rate based on tolerance and IAP measurements</strong>.</li>
<li>Consider <strong>temporary reduction or discontinuation</strong> if IAP increases during EN.</li>
</ul>
<p><em>(R13, grade B, strong consensus, 94 %)</em></p>
<ul>
<li><strong>Clinical Rationale:</strong>
<ul>
<li>Patients with <strong>intra-abdominal hypertension (IAH)</strong> frequently exhibit <strong>digestive intolerance</strong>.</li>
<li><strong>Cautious initiation</strong> of EN is critical:
<ul>
<li>Begin at <strong>20 mL/h</strong></li>
<li>Adjust based on <strong>IAP trends and patient tolerance</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib77">77</a>].</li>
</ul></li>
</ul></li>
<li><strong>Conclusion:</strong>
<ul>
<li>Careful, gradual EN delivery via <strong>nasojejunal route</strong> is recommended in severe AP with elevated IAP, with ongoing <strong>IAP monitoring to guide adjustments</strong>.</li>
</ul></li>
</ul>
</section>
<section id="recomendation-18-pn-in-severe-ap-with-iap-20-mmhg-or-acs" class="slide level3">
<h3>Recomendation 18: PN in Severe AP with IAP &gt;20 mmHg or ACS</h3>
<p>In patients with <strong>severe acute pancreatitis (AP)</strong> and <strong>intra-abdominal pressure (IAP) &gt;20 mmHg</strong> or abdominal compartment syndrome (ACS):</p>
<ul>
<li><strong>Stop enteral nutrition (EN) temporarily</strong>.</li>
<li><strong>Initiate total parenteral nutrition (PN)</strong>.</li>
</ul>
<p><em>(R14, grade GPP, strong consensus, 94 %)</em></p>
<ul>
<li><strong>Clinical Rationale:</strong>
<ul>
<li><strong>IAP &gt;20 mmHg</strong> or ACS presents <strong>critical risk</strong> where EN may worsen the condition.</li>
<li>Switching to <strong>PN prevents further pressure elevation and complications</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib74">74</a>].</li>
</ul></li>
<li><strong>Conclusion:</strong>
<ul>
<li>In severe AP with critically high IAP or ACS, <strong>EN must be interrupted</strong>, and <strong>PN is mandatory</strong> until IAP improves.</li>
</ul></li>
</ul>
</section>
<section id="recomendation-19-severe-ap-with-open-abdomen" class="slide level3">
<h3>Recomendation 19: Severe AP with Open abdomen</h3>
<p>In patients with <strong>severe acute pancreatitis (AP)</strong> and an <strong>open abdomen</strong>:</p>
<ul>
<li><strong>Enteral nutrition (EN)</strong> should be administered, <strong>at least in small amounts</strong>.</li>
<li>Use <strong>supplementary or total parenteral nutrition (PN)</strong> if EN alone does not meet nutritional needs.</li>
</ul>
<p><em>(R15, grade B, strong consensus, 97 %)</em></p>
<ul>
<li><strong>Clinical Rationale:</strong>
<ul>
<li><strong>Decompressive laparotomy (laparostomy)</strong> is required in up to <strong>74% of patients with <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/compartment-syndrome">abdominal compartment syndrome (ACS)</a></strong> during AP [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib78">78</a>].</li>
<li><strong>Cohort studies</strong> show EN is generally <strong>feasible and safe</strong>, though <strong>digestive intolerance rates range from 48% to 67%</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib79">79</a>–<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib84">84</a>].</li>
<li>Two studies reported that early EN in open abdomen patients leads to:
<ul>
<li><strong>Higher fascial closure rates.</strong><br>
</li>
<li><strong>Lower <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/fistula">fistula</a> rates.</strong><br>
</li>
<li><strong>Reduced nosocomial infections.</strong><br>
</li>
<li><strong>Lower hospital costs</strong> [<a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib83">83</a>, <a href="https://www.sciencedirect.com/science/article/pii/S0261561423004594#bib84">84</a>].</li>
</ul></li>
</ul></li>
<li><strong>Conclusion:</strong> Even in the presence of an open abdomen, <strong>EN should be maintained whenever possible</strong>, supported by PN if needed, due to significant clinical benefits.</li>
</ul>
</section>
<section id="questão-6" class="slide level3 scrollable">
<h3>Questão 6</h3>
<p>Você acompanha um paciente com pancreatite aguda grave internado na UTI, cuja pressão intra-abdominal (PIA) é monitorada regularmente. Com base nas evidências atuais sobre nutrição em pacientes com PIA elevada ou abdome aberto, quais das afirmações a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>Quando a PIA está abaixo de 15 mmHg, a nutrição enteral deve ser iniciada precocemente, com monitoramento contínuo da PIA.</li>
<li>Em pacientes com PIA &gt;15 mmHg, a nutrição enteral deve ser suspensa imediatamente e substituída por nutrição parenteral total.</li>
<li>A introdução cautelosa da NE por via nasojejunal, iniciando a 20 mL/h, é recomendada em pacientes com PIA &gt;15 mmHg, desde que monitorada adequadamente.</li>
<li>A presença de síndrome compartimental abdominal (ACS) ou PIA &gt;20 mmHg contraindica a continuação da NE, devendo-se iniciar PN.</li>
<li>Mesmo em pacientes com abdome aberto por laparostomia descompressiva, é recomendado iniciar NE, mesmo que em pequenas quantidades, complementada por PN se necessário.</li>
<li>A presença de abdome aberto contraindica o uso de nutrição enteral devido ao risco elevado de fístulas e infecções.</li>
</ol>
</section>
<section id="questão-6-1" class="slide level3 scrollable">
<h3>Questão 6</h3>
<p>Você acompanha um paciente com pancreatite aguda grave internado na UTI, cuja pressão intra-abdominal (PIA) é monitorada regularmente. Com base nas evidências atuais sobre nutrição em pacientes com PIA elevada ou abdome aberto, quais das afirmações a seguir estão corretas? <em>(Selecione todas as corretas)</em></p>
<ol type="1">
<li>Quando a PIA está abaixo de 15 mmHg, a nutrição enteral deve ser iniciada precocemente, com monitoramento contínuo da PIA. (Correta)</li>
<li>Em pacientes com PIA &gt;15 mmHg, a nutrição enteral deve ser suspensa imediatamente e substituída por nutrição parenteral total. (Incorreta)</li>
<li>A introdução cautelosa da NE por via nasojejunal, iniciando a 20 mL/h, é recomendada em pacientes com PIA &gt;15 mmHg, desde que monitorada adequadamente. (Correta)</li>
<li>A presença de síndrome compartimental abdominal (ACS) ou PIA &gt;20 mmHg contraindica a continuação da NE, devendo-se iniciar PN. (Correta)</li>
<li>Mesmo em pacientes com abdome aberto por laparostomia descompressiva, é recomendado iniciar NE, mesmo que em pequenas quantidades, complementada por PN se necessário. (Correta)</li>
<li>A presença de abdome aberto contraindica o uso de nutrição enteral devido ao risco elevado de fístulas e infecções. (Incorreta)</li>
</ol>
</section>
<section id="fig.-4-management-of-severe-acute-pancreatitis-with-necrosectomy" class="slide level3">
<h3>Fig. 4 Management of Severe Acute pancreatitis with Necrosectomy</h3>

<img data-src="img/gr4_lrg.png" class="r-stretch"><div class="smaller">
<p>ACS, abdominal compartement syndrome; AP, acute pancreatitis; EN, enteral nutrition; <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/abdominal-pressure">IAP</a>, intra-abdominal pressure; PN, parenteral nutrition.</p>
</div>
</section>
<section id="references" class="slide level3 scrollable">
<h3>References</h3>
<ol type="1">
<li><a href="https://www.clinicalnutritionjournal.com/article/S0261-5614(23)00459-4/">ESPEN practical guideline on clinical nutrition in acute and chronic pancreatitis</a>. Arvanitakis, Marianna et al.&nbsp;Clinical Nutrition, Volume 43, Issue 2, 395 - 412.</li>
<li>World Society of the Abdominal Compartment Syndrome (WSACS)</li>
</ol>
<div class="quarto-auto-generated-content">
<p><img src="../usp.png" class="slide-logo"></p>
<div class="footer footer-default">
<p><a href="https://gsplmoura.github.io/Aulas/"><strong>Github pages</strong></a></p>
</div>
</div>
</section></section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="Acute_pancreatitis_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/reveal-chalkboard/plugin.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="Acute_pancreatitis_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleChalkboard(event)\"><kbd>b</kbd> Toggle Chalkboard</a></li>\n<li class=\"slide-tool-item\" data-item=\"5\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.toggleNotesCanvas(event)\"><kbd>c</kbd> Toggle Notes Canvas</a></li>\n<li class=\"slide-tool-item\" data-item=\"6\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.downloadDrawings(event)\"><kbd>d</kbd> Download Drawings</a></li>\n<li class=\"slide-tool-item\" data-item=\"7\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'chalkboard': {"buttons":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: 'c/t',

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'none',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, RevealChalkboard, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const onCopySuccess = function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Copied!");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Copied!");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      }
      const getTextToCopy = function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button:not([data-in-quarto-modal])', {
        text: getTextToCopy
      });
      clipboard.on('success', onCopySuccess);
      if (window.document.getElementById('quarto-embedded-source-code-modal')) {
        // For code content inside modals, clipBoardJS needs to be initialized with a container option
        // TODO: Check when it could be a function (https://github.com/zenorocha/clipboard.js/issues/860)
        const clipboardModal = new window.ClipboardJS('.code-copy-button[data-in-quarto-modal]', {
          text: getTextToCopy,
          container: window.document.getElementById('quarto-embedded-source-code-modal')
        });
        clipboardModal.on('success', onCopySuccess);
      }
        var localhostRegex = new RegExp(/^(?:http|https):\/\/localhost\:?[0-9]*\//);
        var mailtoRegex = new RegExp(/^mailto:/);
          var filterRegex = new RegExp('/' + window.location.host + '/');
        var isInternal = (href) => {
            return filterRegex.test(href) || localhostRegex.test(href) || mailtoRegex.test(href);
        }
        // Inspect non-navigation links and adorn them if external
     	var links = window.document.querySelectorAll('a[href]:not(.nav-link):not(.navbar-brand):not(.toc-action):not(.sidebar-link):not(.sidebar-item-toggle):not(.pagination-link):not(.no-external):not([aria-hidden]):not(.dropdown-item):not(.quarto-navigation-tool):not(.about-link)');
        for (var i=0; i<links.length; i++) {
          const link = links[i];
          if (!isInternal(link.href)) {
            // undo the damage that might have been done by quarto-nav.js in the case of
            // links that we want to consider external
            if (link.dataset.originalHref !== undefined) {
              link.href = link.dataset.originalHref;
            }
          }
        }
      function tippyHover(el, contentFn, onTriggerFn, onUntriggerFn) {
        const config = {
          allowHTML: true,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start',
        };
        if (contentFn) {
          config.content = contentFn;
        }
        if (onTriggerFn) {
          config.onTrigger = onTriggerFn;
        }
        if (onUntriggerFn) {
          config.onUntrigger = onUntriggerFn;
        }
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          if (note) {
            return note.innerHTML;
          } else {
            return "";
          }
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>